The Dalbavancin Market is expected to register a CAGR of 7.3% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Dalbavancin Market report covers analysis by Type (Intravenous Therapy, Oral Type); Applications (Skin Infection, Soft Tissue Infection, Others), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Dalbavancin Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Dalbavancin Market Segmentation
Type- Intravenous Therapy
- Oral Type
- Skin Infection
- Soft Tissue Infection
Strategic Insights
Dalbavancin Market Growth Drivers- Increasing Incidence of Antibiotic-Resistant Infections: Antibiotic-resistant infections, such as MRSA (methicillin-resistant Staphylococcus aureus) and VRE (vancomycin-resistant enterococci), have become a global health crisis. These pathogens are becoming more resistant to conventional antibiotics, making them harder to treat and leading to prolonged illness, higher healthcare costs, and increased mortality. Dalbavancin, being an antibiotic that is active against resistant Gram-positive bacteria, including MRSA, is one of the most significant solutions to this problem. With these resistant infections on the rise, the role of Dalbavancin in the treatment landscape becomes more critical, thereby increasing the demand for this drug.
- Increasing Demand for OPAT: It is the outpatient model of treating acute infections in a hospital setting, allowing for the treatment with IV antibiotics either at home or in dedicated clinics. This new model has more potential with its long half-life, as one dose can be given once a week, thus avoiding a lot of daily visits to hospitals. This reduces the hospital stay for long-term antibiotic treatment. This is both cost-effective and improves patient convenience and satisfaction. With OPAT gaining popularity, the demand for Dalbavancin is also expected to rise.
- Health Infrastructure Expanding in Developing Countries: Underlying this explanation is the expansion of healthcare infrastructure in emerging markets. This involves not only a widening access to better antibiotics that had not previously been available but also an increased accessibility to high-therapeutic-solutions hospitals and clinics. There will be increasing chances to introduce Dalbavancin as an advanced treatment option for severe bacterial infections within these emerging markets. This infrastructure expansion in these regions is accompanied by escalating healthcare spending and translates into a major growth opportunity for the Dalbavancin market.
- Shift Towards Ambulatory Care for Antimicrobial Treatment: Healthcare systems are shifting from inpatient to outpatient models for the delivery of antimicrobial therapy. With advances in medical technology and the increased use of home-based care, patients can receive treatments like Dalbavancin outside of the hospital. This model benefits both patients and healthcare providers by reducing hospital stays, lowering costs, and improving patient comfort. The long dosing intervals provided by dalbavancin can be aligned quite well with outpatient treatment, suggesting that it becomes a drug of choice for patients requiring outpatient parenteral antimicrobial therapy.
- Focus on Long-Acting Antibiotics: The healthcare industry is more and more turning to producing and applying long-acting antibiotics. Such drugs have advantages such as less frequent dosing and better compliance by the patients. Dalbavancin represents a prime example, as its administration is done once a week. Long-acting antibiotics reduce the need for frequent administration, which is especially useful for chronic infection patients. Therefore, this trend of long-acting medications would lead to a steady increase in the market share of Dalbavancin as both the patients and providers wish to get convenient and effective therapy.
- Increasing Adoption of Combination Therapies: While Dalbavancin is effective on its own, it is also often used in combination with other antibiotics to broaden its spectrum of activity, particularly for complicated or multi-drug resistant infections. Combination therapies are becoming increasingly popular, as they can enhance the effectiveness of treatment and prevent the development of resistance. As resistance patterns evolve, Dalbavancin’s role in combination therapies is likely to increase, further expanding its use and market penetration.
- Potential for Expansion in Hospital and Outpatient Settings: There is still much room for growth because Dalbavancin is currently being used in both hospital and outpatient settings, but its application will then soar as it offers the possibility of being administered to patients even in their home settings. As outpatient care generally continues to rise around the world, Dalbavancin will have a chance to serve patients beyond hospital settings.
- R&D for more indications: The main indication for Dalbavancin remains SSTIs; however, much research is done on its possibilities for other kinds of infections including osteomyelitis, endocarditis, and pneumonia. If this antibiotic proves useful in these cases as well according to clinical tests, Dalbavancin can be made as first-line treatment in more infections as well, with more revenue channels and a wide market.
- Investment in developing antibiotics : Growing antibiotic resistance threatens to worsen conditions. For instance, research funding on newer antibiotics by large companies, organizations, and even governments has dramatically improved investments globally in new product developments in that segment. DALB The growth investment of one such new-class antibiotics dalbavancin could improve not just with improved versions of these newer products that make their positioning even stronger while creating wider possibilities in their new usages.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Dalbavancin Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Dalbavancin Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Dalbavancin Market are Increasing Incidence of Antibiotic-Resistant Infections, Increasing Demand for OPAT, and Health Infrastructure Expanding in Developing Countries
The key future trends of the market are Shift Towards Ambulatory Care for Antimicrobial Treatment, Focus on Long-Acting Antibiotics, and Increasing Adoption of Combination Therapies:
The leading players operating in the Dalbavancin Market include AbbVie Inc., Amgen Inc., F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Novartis AG, Pfizer Inc.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Dalbavancin Market - By Type
1.3.2 Dalbavancin Market - By Applications
1.3.3 Dalbavancin Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. DALBAVANCIN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. DALBAVANCIN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. DALBAVANCIN MARKET - GLOBAL MARKET ANALYSIS
6.1. DALBAVANCIN - GLOBAL MARKET OVERVIEW
6.2. DALBAVANCIN - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. DALBAVANCIN MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. INTRAVENOUS THERAPY
7.3.1. Overview
7.3.2. Intravenous Therapy Market Forecast and Analysis
7.4. ORAL TYPE
7.4.1. Overview
7.4.2. Oral Type Market Forecast and Analysis
8. DALBAVANCIN MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATIONS
8.1. OVERVIEW
8.2. APPLICATIONS MARKET FORECASTS AND ANALYSIS
8.3. SKIN INFECTION
8.3.1. Overview
8.3.2. Skin Infection Market Forecast and Analysis
8.4. SOFT TISSUE INFECTION
8.4.1. Overview
8.4.2. Soft Tissue Infection Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. DALBAVANCIN MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Dalbavancin Market Overview
9.1.2 North America Dalbavancin Market Forecasts and Analysis
9.1.3 North America Dalbavancin Market Forecasts and Analysis - By Type
9.1.4 North America Dalbavancin Market Forecasts and Analysis - By Applications
9.1.5 North America Dalbavancin Market Forecasts and Analysis - By Countries
9.1.5.1 United States Dalbavancin Market
9.1.5.1.1 United States Dalbavancin Market by Type
9.1.5.1.2 United States Dalbavancin Market by Applications
9.1.5.2 Canada Dalbavancin Market
9.1.5.2.1 Canada Dalbavancin Market by Type
9.1.5.2.2 Canada Dalbavancin Market by Applications
9.1.5.3 Mexico Dalbavancin Market
9.1.5.3.1 Mexico Dalbavancin Market by Type
9.1.5.3.2 Mexico Dalbavancin Market by Applications
9.2. EUROPE
9.2.1 Europe Dalbavancin Market Overview
9.2.2 Europe Dalbavancin Market Forecasts and Analysis
9.2.3 Europe Dalbavancin Market Forecasts and Analysis - By Type
9.2.4 Europe Dalbavancin Market Forecasts and Analysis - By Applications
9.2.5 Europe Dalbavancin Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Dalbavancin Market
9.2.5.1.1 Germany Dalbavancin Market by Type
9.2.5.1.2 Germany Dalbavancin Market by Applications
9.2.5.2 France Dalbavancin Market
9.2.5.2.1 France Dalbavancin Market by Type
9.2.5.2.2 France Dalbavancin Market by Applications
9.2.5.3 Italy Dalbavancin Market
9.2.5.3.1 Italy Dalbavancin Market by Type
9.2.5.3.2 Italy Dalbavancin Market by Applications
9.2.5.4 Spain Dalbavancin Market
9.2.5.4.1 Spain Dalbavancin Market by Type
9.2.5.4.2 Spain Dalbavancin Market by Applications
9.2.5.5 United Kingdom Dalbavancin Market
9.2.5.5.1 United Kingdom Dalbavancin Market by Type
9.2.5.5.2 United Kingdom Dalbavancin Market by Applications
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Dalbavancin Market Overview
9.3.2 Asia-Pacific Dalbavancin Market Forecasts and Analysis
9.3.3 Asia-Pacific Dalbavancin Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Dalbavancin Market Forecasts and Analysis - By Applications
9.3.5 Asia-Pacific Dalbavancin Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Dalbavancin Market
9.3.5.1.1 Australia Dalbavancin Market by Type
9.3.5.1.2 Australia Dalbavancin Market by Applications
9.3.5.2 China Dalbavancin Market
9.3.5.2.1 China Dalbavancin Market by Type
9.3.5.2.2 China Dalbavancin Market by Applications
9.3.5.3 India Dalbavancin Market
9.3.5.3.1 India Dalbavancin Market by Type
9.3.5.3.2 India Dalbavancin Market by Applications
9.3.5.4 Japan Dalbavancin Market
9.3.5.4.1 Japan Dalbavancin Market by Type
9.3.5.4.2 Japan Dalbavancin Market by Applications
9.3.5.5 South Korea Dalbavancin Market
9.3.5.5.1 South Korea Dalbavancin Market by Type
9.3.5.5.2 South Korea Dalbavancin Market by Applications
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Dalbavancin Market Overview
9.4.2 Middle East and Africa Dalbavancin Market Forecasts and Analysis
9.4.3 Middle East and Africa Dalbavancin Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Dalbavancin Market Forecasts and Analysis - By Applications
9.4.5 Middle East and Africa Dalbavancin Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Dalbavancin Market
9.4.5.1.1 South Africa Dalbavancin Market by Type
9.4.5.1.2 South Africa Dalbavancin Market by Applications
9.4.5.2 Saudi Arabia Dalbavancin Market
9.4.5.2.1 Saudi Arabia Dalbavancin Market by Type
9.4.5.2.2 Saudi Arabia Dalbavancin Market by Applications
9.4.5.3 U.A.E Dalbavancin Market
9.4.5.3.1 U.A.E Dalbavancin Market by Type
9.4.5.3.2 U.A.E Dalbavancin Market by Applications
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Dalbavancin Market Overview
9.5.2 South and Central America Dalbavancin Market Forecasts and Analysis
9.5.3 South and Central America Dalbavancin Market Forecasts and Analysis - By Type
9.5.4 South and Central America Dalbavancin Market Forecasts and Analysis - By Applications
9.5.5 South and Central America Dalbavancin Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Dalbavancin Market
9.5.5.1.1 Brazil Dalbavancin Market by Type
9.5.5.1.2 Brazil Dalbavancin Market by Applications
9.5.5.2 Argentina Dalbavancin Market
9.5.5.2.1 Argentina Dalbavancin Market by Type
9.5.5.2.2 Argentina Dalbavancin Market by Applications
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. DALBAVANCIN MARKET, KEY COMPANY PROFILES
11.1. ABBVIE INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. AMGEN INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. F. HOFFMANN-LA ROCHE LTD
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GILEAD SCIENCES, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. GLAXOSMITHKLINE PLC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. JOHNSON AND JOHNSON SERVICES, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MERCK AND CO.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. NOVARTIS AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. PFIZER INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SANOFI
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. AbbVie Inc.
2. Amgen Inc.
3. F. Hoffmann-La Roche Ltd
4. Gilead Sciences, Inc.
5. GlaxoSmithKline plc
6. Johnson & Johnson Services, Inc.
7. Merck & Co.
8. Novartis AG
9. Pfizer Inc.
10. Sanofi
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For